Actuate Therapeutics, Inc. Common stock Total Liabilities
Actuate Therapeutics, Inc. Common stock total liabilities. Based on the latest financial reports, Actuate Therapeutics, Inc. Common stock (ACTU) has total liabilities worth $6.78 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Actuate Therapeutics, Inc. Common stock (ACTU) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Actuate Therapeutics, Inc. Common stock (2022–2024)
Total liabilities of Actuate Therapeutics, Inc. Common stock from 2022 to 2024. This chart illustrates how Actuate Therapeutics, Inc. Common stock's total liabilities have evolved over time, based on quarterly financial data.
Actuate Therapeutics, Inc. Common stock Competitors by Total Liabilities
The table below lists competitors of Actuate Therapeutics, Inc. Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Workspace Group PLC
LSE:WKP
|
UK | GBX955.40 Million |
|
Terragen Holdings Ltd
AU:TGH
|
Australia | AU$1.07 Million |
|
Sun&L Co Ltd
KO:002820
|
Korea | ₩250.22 Billion |
|
XIAO-I Corporation American Depositary Shares
NASDAQ:AIXI
|
USA | $119.18 Million |
|
Norwood Systems Ltd
AU:NOR
|
Australia | AU$1.63 Million |
|
Jaya Trishindo Tbk PT
JK:HELI
|
Indonesia | Rp99.55 Billion |
|
Eros International Media Limited
NSE:EROSMEDIA
|
India | Rs10.25 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down Actuate Therapeutics, Inc. Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Actuate Therapeutics, Inc. Common stock total assets.
Liquidity & Leverage Metrics
Actuate Therapeutics, Inc. Common stock Total Liabilities Ratios Explained
Actuate Therapeutics, Inc. Common stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Actuate Therapeutics, Inc. Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Actuate Therapeutics, Inc. Common stock (2022–2024)
The table below shows the annual total liabilities of Actuate Therapeutics, Inc. Common stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.21 Million | -91.02% |
| 2023-12-31 | $102.62 Million | +1716.08% |
| 2022-12-31 | $5.65 Million | -- |
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of… Read more